Antibiotic Prophylaxis for Transrectal Prostate Biopsy
Status:
Completed
Trial end date:
2016-08-01
Target enrollment:
Participant gender:
Summary
This study is being conducted in men scheduled to undergo transrectal ultrasound-guided
prostate biopsy (TRUSP). Traditionally prior to prostate biopsy, an antibiotic,
ciprofloxacin, has been given to men to prevent biopsy-related infections. In recent years as
ciprofloxacin resistance has increased in the community, more and more men are becoming
infected with ciprofloxacin-resistant bacteria after prostate biopsy. This study is being
done to determine if obtaining rectal swab cultures and choosing antibiotics based on these
culture results will result in fewer infectious complications than giving all men
ciprofloxacin.
The investigators will compare 2 groups: men whose rectal swabs do not show
ciprofloxacin-resistant bacteria will receive ciprofloxacin prior to biopsy, and men whose
swabs do show ciprofloxacin-resistant bacteria will receive alternative antibiotics based on
their culture results. Our hypothesis is that these 2 groups will have equal numbers of
post-biopsy infectious complications and both groups will have fewer infectious complications
than a historical group who received empiric ciprofloxacin without the benefit of rectal swab
culture results.